ResearcherHellenic Oncology Research GroupActive in the last 2 years

Vassilis Georgoulias

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2218-2522; OpenAlex author ID A5077410158, A5108460871. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Athanasios Panayotis Kotsakis · 2 shared papers, 2014–2025 · strength 0.26
- Paper Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDAC. DOI 10.1007/s00262-025-04190-1 ↗
- Paper Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic … DOI 10.1007/s00280-014-2509-6 ↗
Anastasia Xagara · 1 shared paper, 2025 · strength 0.22
- Paper Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDAC. DOI 10.1007/s00262-025-04190-1 ↗
Galatea Kallergi · 1 shared paper, 2025 · strength 0.22
- Paper Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDAC. DOI 10.1007/s00262-025-04190-1 ↗
Ioannis S. Pateras · 1 shared paper, 2025 · strength 0.22
- Paper Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDAC. DOI 10.1007/s00262-025-04190-1 ↗
Ourania Katopodis · 1 shared paper, 2014 · strength 0.04
- Paper Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic … DOI 10.1007/s00280-014-2509-6 ↗
Nikolaos K. Kentepozidis · 1 shared paper, 2014 · strength 0.04
- Paper Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic … DOI 10.1007/s00280-014-2509-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.